Opioid Rapid Response System: Naloxone Training in Communities
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jan 25, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Opioid Rapid Response System (ORRS) trial is studying a new way to help people respond quickly to opioid overdoses by training everyday citizens to use naloxone, a life-saving medication that can reverse overdoses. The goal is to reduce the number of deaths caused by opioid overdoses, which has become a serious problem in many communities. The ORRS project will leverage the PulsePoint health app, which already helps people respond to cardiac emergencies, to notify users about overdose incidents and provide training on how to use naloxone effectively.
To participate in this trial, you need to be at least 18 years old, fluent in English, and live in a community that uses the PulsePoint app. You should also have access to mobile data and be able to download apps on your smartphone. If you join, you can expect to receive training on how to administer naloxone and to take part in a study that will help shape future efforts to prevent opioid overdoses. This initiative is especially important as it aims to create a system that is both efficient and effective in saving lives during emergencies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Citizens who live in participating PulsePoint communities
- • Must to be 18 and older
- • Must be fluent in English
- • Must have access to the mobile data and able to download and use apps in a smartphone
- Exclusion Criteria:
- • Citizens who do not live in participating PulsePoint communities
- • Under 18-year-old
- • Citizens who are not fluent in English
- • Citizens who do not have access to mobile data and unable to download and use apps in a smartphone.
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Hye Jeong Choi
Principal Investigator
Univeristy of Missouri
Michael Hecht
Principal Investigator
Real Prevention
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported